# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
This registration statement contains: a base prospectus which covers the offering, issuance and sale by us of up to $75,000,000...
HC Wainwright & Co. analyst Emily Bodnar maintains Imunon (NASDAQ:IMNN) with a Buy and lowers the price target from $13 ...
A second site at a tertiary center in Boston, MA is expected to be activated in the next few weeks.Proof-of-concept study for I...
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.7...
Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experienc...
IMUNON, Inc. (NASDAQ:IMNN) ("IMUNON" or the "Company"), a clinical-stage drug-development company focused on de...